Compass Pathways: Psilocybin treatment results in bipolar II published in JAMA

Compass Pathways announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder . Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022…There was no increase in the suicidality score based on the MADRS, no manic symptoms and no unexpected adverse events or difficulties with the dosing sessions reported throughout the study. The most common adverse event was headache reported by 4 out of 15 participants on the day of dosing, with symptoms resolving within 24 hours. “We’re pleased that our study has been recognized and published by a highly regarded peer-reviewed journal,” said Dr Scott Aaronson, MD, Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt. “In what we believe to be the first study of its kind, we saw a significant number of patients experience relief from their bipolar II depression symptoms after a single 25mg dose of COMP360 psilocybin treatment. These findings need to be validated in larger studies.”